Punitive tax provision that applies to e." For entrepreneurs working within the industry, Salzhauer advises that they figure out the vertical first. That also means that entrepreneurs should thinking about their exit horizon, should they be interested in one, since investigatory drug processes take many years and are often significantly more expensive on the front end, he adds. While he admits it's probably too early to tell, Salzhauer hazards a guessherapists are also trained with MDMA and psilocybin, and are eager to administer MDMA and psilocybin once it becomes legal.
That MDMA-based therapies are closer to receiving approval compared with other psychedelic therapies. As research continues and practitioners prepare for new treatments, there's clear interest from the public. A Harris Poll survey from January 2022 showed that 65 percent of Americans with USA Phone Number Data anxiety, depression, or PTSD expressed an interest in psychedelic therapies for mental health. Antidepressants used to treat these conditions are dated and come with their own deluge of side effects. Startups are already under way.
Take Enthea, a Boston-based third-party administrator of health insurance plans that offers psychedelic health care as a benefit that employers can integrate into their own plans. While the company isn't working closely with major insurance carriers just yet, it's able to maneuver around insurers by offering add-on benefits. Enthea currently helps offer ketamine-assisted therapy to workplaces, but Sherry Rais, Enthea's founder, says that the plan is to include MDMA therapy as a benefit and, eventually, psilocybin therapy--along with other psychedelics as they win approval. The company is already building out its policies for MDMA-assisted therapy, Rais says, just as it did for ketamine-assisted therapy two years before it launched. "Even as we're building our provider network," she says, "what you'll see is a lot of these ketamine.